OverviewSuggest Edit

The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life science focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS).

TypePublic
Founded1999
HQParis, FR
Websitecellectis.com
Employee Ratings3.3

Latest Updates

Employees (est.) (May 2021)272(+8%)
Job Openings23
Revenue (FY, 2017)$33.7 M(-40%)
Share Price (Jun 2021)€12
Cybersecurity ratingDMore

Key People/Management at Cellectis

André Choulika

André Choulika

Chief Executive Officer & Board Director
Carrie Brownstein

Carrie Brownstein

Chief Medical Officer
Leopold Bertea

Leopold Bertea

Senior Vice President of Technical Operations - Europe
Philippe Duchateau

Philippe Duchateau

Chief Scientific Officer
Eric Dutang

Eric Dutang

Chief Financial Officer
Steve Doares

Steve Doares

Senior Vice President, US Manufacturing and Site Head
Show more

Cellectis Office Locations

Cellectis has offices in Paris, Lyon, New York and Raleigh
Paris, FR (HQ)
8 Rue de la Croix Jarry
Lyon, FR
28 Rue Laennec
New York, NY, US
430 E 29th St
Raleigh, NC, US
2500 Sumner Blvd
Show all (4)

Cellectis Financials and Metrics

Cellectis Revenue

Cellectis's revenue was reported to be $33.72 m in FY, 2017 which is a 40.3% decrease from the previous period.
USD

Revenue (FY, 2017)

33.7m

Revenue growth (FY, 2016 - FY, 2017), %

(40.3%)

Net income (FY, 2017)

(103.7m)

Market capitalization (4-Jun-2021)

515.1m

Closing stock price (4-Jun-2021)

12.0

Cash (31-Dec-2017)

256.4m
Cellectis's current market capitalization is €515.1 m.
USDFY, 2015FY, 2016FY, 2017

Revenue

56.4m56.4m33.7m

Revenue growth, %

0%(40%)

General and administrative expense

27.2m43.4m44.8m

R&D expense

52.4m78.5m79.2m
USDFY, 2015FY, 2016FY, 2017

Cash

314.2m254.6m256.4m

Accounts Receivable

6.0m3.6m2.8m

Inventories

118.0k118.0k250.0k

Current Assets

334.2m312.5m323.2m
USDFY, 2015FY, 2016FY, 2017

Net Income

(20.4m)(67.3m)(103.7m)

Depreciation and Amortization

1.7m2.2m3.4m

Inventories

(23.0k)50.0k(109.0k)

Accounts Payable

2.7m(4.4m)(335.0k)
USDFY, 2015

Financial Leverage

1.3 x

P/E Ratio

(16.2)
Show all financial metrics

Cellectis Revenue Breakdown

Embed Graph

Cellectis revenue breakdown by geographic segment: 98.0% from France and 2.0% from Other

Cellectis Cybersecurity Score

Cybersecurity ratingPremium dataset

D

63/100

SecurityScorecard logo

Cellectis Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

0-29

out of 100

CSRHub logo

Cellectis Online and Social Media Presence

Embed Graph

Cellectis News and Updates

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France.

Global Stem Cell Therapy Market Report 2021-2030 Featuring Anterogen, JCR Pharma, Medipost, Osiris Therapeutics, Pharmicell, Astellas Pharma, Cellectis, Celyad, Novadip Biosciences, and Gamida Cell

Dublin, May 17, 2021 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. Stem Cell Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030 provides the strategists, marke…

Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells (“UCART”) in the field of immuno-oncol…

Cellectis Completes Sale of $47 million through its ATM program

NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field of i…

Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells

CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Celle…

Thinking about buying stock in Aphria, Drive Shack, Gevo, Cellectis, or Sesen Bio?

NEW YORK, Dec. 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APHA, DS, GEVO, CLLS, and SESN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Cellectis Blogs

Cellectis’ Innovation Days event highlighted New Product Development,  New Genome Surgery Platform .HEAL, and Manufacturing Capabilities

Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidates for solid tumors UCARTMESO (targeting Mesothelin), UCARTMUC1 (targeting Mucin 1)_, UCARTFAP (targeting …

Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

May 11, 2021 – Paris - Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells (“UCART”) in the field of immuno-oncology, and Sanofi (Eu…

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021

Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers Five partnered allogeneic CAR-T product candidates in clinical development through our col…

Cellectis’ Annual Shareholders’ General Meeting to be Held on June 1, 2021

April 26, 2021 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) Dear Shareholders, In the context of the Covid-19 pandemic and in accordance with Ordinance no. 2020-321 of March 25, 2020, the provisions of which were extended until July 31, 2021 by Decree no. 2021-255 of March…

Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq

New York, NY, March 29, 2021 – Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field of immuno-oncology, …

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results

Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r …
Show more

Cellectis Frequently Asked Questions

  • When was Cellectis founded?

    Cellectis was founded in 1999.

  • Who are Cellectis key executives?

    Cellectis's key executives are André Choulika, Carrie Brownstein and Leopold Bertea.

  • How many employees does Cellectis have?

    Cellectis has 272 employees.

  • What is Cellectis revenue?

    Latest Cellectis annual revenue is $33.7 m.

  • What is Cellectis revenue per employee?

    Latest Cellectis revenue per employee is $124 k.

  • Who are Cellectis competitors?

    Competitors of Cellectis include Allogene Therapeutics, EMS Pharma and Biocon.

  • Where is Cellectis headquarters?

    Cellectis headquarters is located at 8 Rue de la Croix Jarry, Paris.

  • Where are Cellectis offices?

    Cellectis has offices in Paris, Lyon, New York and Raleigh.

  • How many offices does Cellectis have?

    Cellectis has 4 offices.